Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 0.59 · gapped below the open, never looked back. High/low 0.57 at 10:30 am ET, 0.56 at 3:45 pm ET.
Citius Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Mino-Lok® – LMB has a patent and technology license agreement with Novel Anti-Infective Therapeutics, Inc. ("NAT") to develop and commercialize Mino-Lok on an exclusive, worldwide sub-licensable basis, as amended.”
FILING10-K0001213900-25-125333cik 0001506251
“On October 6, 2020, our subsidiary NoveCite entered into a license agreement with Novellus Therapeutics Limited, whereby NoveCite acquired an exclusive, worldwide”
FILING10-K0001213900-25-125333cik 0001506251
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”
FILING10-K0001213900-25-125333cik 0001506251
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”
FILING10-K0001213900-25-125333cik 0001506251
“LYMPHIR, Citius Oncology has entered into distribution agreements with Cardinal Health, Cencora and McKesson Corporation.”
FILING10-K0001213900-25-125333cik 0001506251
“In September 2021, the Company entered into an asset purchase agreement with Dr. Reddy's and a license agreement with Eisai to acquire an exclusive license of E7777 (denileukin diftitox), an oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma.”
FILING10-K0001213900-25-125333cik 0001506251
“In September 2021, the Company entered into an asset purchase agreement with Dr. Reddy's and a license agreement with Eisai to acquire an exclusive license of E7777 (denileukin diftitox), an oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma.”
FILING10-K0001213900-25-125333cik 0001506251
“Citius Oncology has contracted with EVERSANA an innovative AI platform, to support the launch and commercialization of LYMPHIR whereby”
FILING10-K0001213900-25-125333cik 0001506251
Watchlist prices, news filtered to it, and its next report on your desk.
Citius Pharmaceuticals, Inc. has 5 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Citius Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
CTXR (Citius Pharmaceuticals, Inc.) has 5 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: MCK −0.14%, in healthcare.